DevonshireVLapierreYMacdonellR, et al. The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol2011; 18: 69–77.
2.
McEwanLBrownJPoirierJ, et al. Best practices in skin care for the multiple sclerosis patient receiving injectable therapies. Int J MS Care2010; 12: 177–189.
3.
TreadawayKCutterGSalterA, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol2009; 256: 568–576.
4.
CalabresiPAKieseierBCArnoldDL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. Lancet Neurol13(7): 657–665.
ButtmannMGoebelerMToksoyA, et al. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol2005; 168: 175–182.
7.
MosesHJrBrandesDW. Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. Curr Med Res Opin2008; 24: 2679–2690.
8.
VerdundiCantognoERussellSSnowT. Understanding and meeting injection device needs in multiple sclerosis: A survey of patient attitudes and practices. Patient Prefer Adherence2011; 5: 173–180.
9.
FrohmanEMBrannonKAlexanderS, et al. Disease modifying agent related skin reactions in multiple sclerosis: Prevention, assessment, and management. Mult Scler2004; 10: 302–307.
10.
GarbeCKrasagakisK. Effects of interferons and cytokines on melanoma cells. J Invest Dermatol1993; 100(2 Suppl.): 239S–244S.
11.
TsilikaKTranATrucchiR, et al. Secondary hyperpigmentation during interferon alpha treatment for chronic hepatitis C virus infection. JAMA Dermatol2013; 149(6): 675–677.
12.
KocerBNazlielBOztasM, et al. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: A case report. Eur J Neurol2009; 16(4): e78–e79.
13.
EdgarCMBrunetDGFentonP, et al. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci2004; 31: 58–63.
14.
PorterJBeufAHNordlundJJ, et al. Psychological reaction to chronic skin disorders: A study of patients with vitiligo. Gen Hosp Psychiatry1979; 1(1): 73–77.
15.
KernSSchrempfWSchneiderH, et al. Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. Mult Scler2009; 15(6): 752–758.
